U.S. FDA issues 4 observations to Aurobindo arm’s formulation unit

The U.S. Food and Drug Administration (U.S. FDA) has issued 4 observations to a formulation manufacturing installation of Aurobindo Pharma subsidiary Eugia Pharma Specialities adjacent Hyderabad.

The installation (Unit-I), successful Ranga Reddy district, was inspected from February 16-27 and connected decision the observations were issued. It is the 3rd installation of the generic drugmaker and its subsidiary to person U.S. FDA observations this month.

On February 6, the U.S. FDA had issued 11 observations to different formulation manufacturing installation (Unit III) of Eugia Pharma Specialities successful Hyderabad and wrong a week issued nine observations to the oral coagulated dosage manufacturing portion of Aurobindo Pharma adjacent Hyderabad.

In a filing connected Friday, connected the latest development, Aurobindo Pharma said determination is nary interaction connected the company’s financials oregon operations owed to the said action. It volition respond to the regulator wrong the stipulated timelines.